BHB supplement with CAR-T for lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at adding a supplement called beta-hydroxybutyrate (BHB) to standard CAR-T therapy for people with large B-cell lymphoma. It may help improve how well the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have been diagnosed with large B-cell lymphoma (a type of blood cancer)
- You plan to receive one of the standard CAR-T therapies called Yescarta or Kymriah
- You are not allergic to energy drinks
- You do not have inflammatory bowel disease or type 1 diabetes, and your kidneys work well enough (a GFR of 30 or higher)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study looks at giving CAR-T cell therapy first, then follow-up “bispecific” antibody medicines to help keep large B-cell lymphoma from coming back. It’s for people whose lymphoma returned or did not respond to prior standard treatments and who still have measurable disease on scans.
This trial tests a CAR-T cell treatment made to target CD19 on lymphoma cells (PL001). It’s for people whose B-cell lymphoma has come back or not responded to standard treatments, aiming to shrink the cancer and help control the disease.
This trial tests whether adding low-dose total body radiation before standard CAR-T cell therapy (Kymriah) helps people with relapsed or refractory large B-cell lymphoma. It aims to improve the effectiveness of the CAR-T cells.
This study tests a new way to prepare for CAR-T cell therapy for people with aggressive B-cell lymphoma who cannot have a stem cell transplant. Instead of using strong chemotherapy before CAR-T, this trial uses a pill-based regimen to keep the cancer under control and help the CAR-T cells work better.
This study tests a customized cancer treatment called CD19 CAR-T for people newly diagnosed with certain high-risk large B-cell lymphoma. It aims to see whether this treatment can help control the lymphoma, especially in higher-risk cases.
This trial tests combining an experimental drug (CLS-015) with a standard CAR-T cell therapy for people with large B-cell lymphoma whose disease is stable or progressing. It aims to see if the combination is safe and might improve treatment outcomes.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.